Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Japan Exchange
09:30:00 09/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 5,843.00 JPY | +0.46% |
|
+3.54% | +20.85% |
| 10-08 | Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom | RE |
| 10-07 | Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule | MT |
| Market Cap | 9,330B 58.92B 52.66B 48.87B 44.58B 84.08B 5,703B 84.51B 584B 230B 2,911B 221B 217B | P/E 2027 * |
46.3x | P/E 2028 * | 29.4x |
|---|---|---|---|---|---|
| Enterprise Value | 13,236B 83.59B 74.71B 69.33B 63.24B 119B 8,091B 120B 829B 326B 4,130B 314B 307B | EV / Sales 2027 * |
2.82x | EV / Sales 2028 * | 2.72x |
| Free-Float |
99.25% | Yield 2027 * |
3.5% | Yield 2028 * | 3.57% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4502 | Delayed | |
Tradegate
| TKD | Real-time | |
|
OTC Markets
| TKPHF | Delayed | |
|
Boerse Muenchen
| TKD | Real-time | |
|
Deutsche Boerse AG
| TKD | Delayed | |
|
Börse Stuttgart
| TKD | Delayed | |
|
Wiener Boerse
| TKD | End-of-day quote |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +0.46% | ||
| 1 week | +3.54% | ||
| Current month | +1.09% | ||
| 1 month | +3.29% | ||
| 3 months | +9.03% | ||
| 6 months | +1.94% | ||
| Current year | +20.85% |
| 1 week | 5,606 |  | 5,870 |
| 1 month | 5,606 | | 6,030 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/14/26 A | Sell | Executive/Senior Manager | -34,535 | 0.0022% | ||
| 9/2/26 A | Sell | Chief Technology Officer | -116,191 | 0.0073% | ||
| 8/19/26 A | Sell | Chief Technology Officer | -19,651 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.46% | +3.54% | +38.39% | +27.63% | 58.92B | |
| +0.83% | +3.19% | +41.49% | +103.56% | 1,051B | |
| +1.93% | +2.11% | +37.08% | +65.09% | 630B | |
| +1.49% | +5.19% | +19.94% | +85.69% | 489B | |
| +2.26% | +0.90% | +69.32% | +40.53% | 359B | |
| +1.45% | +3.50% | +23.29% | +41.62% | 344B | |
| +1.17% | +2.37% | +13.47% | +33.64% | 272B | |
| +0.89% | +1.08% | -6.13% | +9.29% | 246B | |
| +1.82% | +2.94% | +42.99% | +52.95% | 224B | |
| +2.77% | +4.44% | +29.01% | +98.99% | 187B | |
| Average | +1.51% | +2.63% | +30.89% | +55.90% | 386.26B | |
| Weighted average by Cap. | +1.45% | +2.46% | +33.43% | +68.38% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,701B 29.69B 26.53B 24.62B 22.46B 42.37B 2,873B 42.58B 294B 116B 1,467B 112B 109B | 4,788B 30.24B 27.02B 25.08B 22.88B 43.15B 2,927B 43.37B 300B 118B 1,494B 114B 111B |
| Net income | 196B 1.24B 1.11B 1.03B 939M 1.77B 120B 1.78B 12.31B 4.84B 61.31B 4.66B 4.56B | 323B 2.04B 1.82B 1.69B 1.54B 2.91B 197B 2.92B 20.22B 7.96B 101B 7.66B 7.49B |
| Net Debt | 3,907B 24.67B 22.05B 20.46B 18.67B 35.21B 2,388B 35.39B 245B 96.3B 1,219B 92.7B 90.68B | 3,702B 23.38B 20.9B 19.39B 17.69B 33.36B 2,263B 33.53B 232B 91.26B 1,155B 87.85B 85.94B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/10/26 | ¥5,843.00 | +0.46% | 3,664,000 |
| 08/10/26 | ¥5,816.00 | +0.87% | 4,535,300 |
| 07/10/26 | ¥5,766.00 | +0.82% | 3,222,600 |
| 06/10/26 | ¥5,719.00 | +1.42% | 3,536,400 |
| 05/10/26 | ¥5,639.00 | -0.07% | 3,269,900 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
